Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00634452 | Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma | PHASE1 | COMPLETED | 22 | — | — | Feb 1, 2008 | Jan 1, 2010 | Dec 6, 2012 | 6 | United States |
| Arm | Type | Description |
|---|---|---|
| MDX-1401 | EXPERIMENTAL | MDX-1401 iv at various doses |
| Name | Type | Description |
|---|---|---|
| MDX-1401 | BIOLOGICAL | IV weekly for 4 weeks |
Inclusion Criteria: * Diagnosis of CD30-positive HL by immunohistochemistry or flow cytometry * Must have failed or relapsed following second line chemotherapy or radiation or failed/relapsed following autologous stem cell transplant * Bi-measurable disease * ECOG Performance Status of 0 - 2 * Meet...